Androgen Receptor Inhibitors in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

恩扎鲁胺 医学 中止 前列腺癌 耐受性 内科学 队列 雄激素受体 肿瘤科 不利影响 癌症
作者
Daniel J. George,Alicia K. Morgans,Niculae Constantinovici,Nasreen Khan,Javeed Khan,Guifang Chen,Vlasta Hlebec,Neal D. Shore
出处
期刊:JAMA network open [American Medical Association]
卷期号:7 (8): e2429783-e2429783
标识
DOI:10.1001/jamanetworkopen.2024.29783
摘要

Importance Novel androgen receptor inhibitors (ARIs; darolutamide, enzalutamide, and apalutamide) are standard-of-care treatments for nonmetastatic castration-resistant prostate cancer (nmCRPC). However, there are sparse data comparing their clinical use and tolerability. Objective To compare clinical use and outcomes for darolutamide, enzalutamide, and apalutamide in patients with nmCRPC. Design, Setting, and Participants This retrospective cohort study reviewed electronic medical records from the Precision Point Specialty network of US urology practices. Eligible patients had nmCRPC and no prior novel hormonal therapy and initiated novel ARI treatment between August 1, 2019, and March 31, 2022. Data were analyzed from February 1, 2019, to December 31, 2022. Exposures Patients were prescribed darolutamide, enzalutamide, or apalutamide as their first novel ARI for nmCRPC. Main Outcomes and Measures The main outcome was a composite of 2 end points, treatment discontinuation and progression to metastatic CRPC (mCRPC), whichever occurred first. Both end points were also assessed separately. Results All 870 patients meeting eligibility criteria were included (362 receiving darolutamide [41.6%]; 382, enzalutamide [43.9%]; 126, apalutamide [14.5%]); mean (SD) age was 78.8 (8.7) years. Self-reported race was Black or African American in 187 patients (21.5%), White in 585 (67.2%), and other or unknown in 98 (11.3%). The darolutamide cohort had lower proportions of patients with a composite end point event (134 [37.0%] vs 201 [52.6%] for enzalutamide and 66 [52.4%] for apalutamide), discontinuation (110 [30.4%] for darolutamide vs 156 [40.8%] for enzalutamide and 58 [46.0%] for apalutamide), and progression to mCRPC (64 [17.7%] for darolutamide vs 108 [28.3%] for enzalutamide and 35 [27.8%] for apalutamide) during the study period. After adjusting for baseline covariates, patients receiving darolutamide had a lower risk of a composite end point event compared with enzalutamide (risk reduction, 33.8%; hazard ratio [HR], 0.66 [95% CI, 0.53-0.84]) and apalutamide (risk reduction, 35.1%; HR, 0.65 [95% CI, 0.48-0.88]). Similarly, patients receiving darolutamide had a lower risk of discontinuation compared with enzalutamide (risk reduction, 27.4%; HR, 0.73 [95% CI, 0.56-0.94]) and apalutamide (risk reduction, 39.1%; HR, 0.61 [95% CI, 0.44-0.85]) and a lower risk of progression to mCRPC compared with enzalutamide (risk reduction, 40.6%; HR, 0.59 [95% CI, 0.43-0.82]) and apalutamide (risk reduction, 35.3%; HR, 0.65 [95% CI, 0.42-0.99]). There was no difference between enzalutamide and apalutamide treatment across outcomes. Conclusions and Relevance In this large cohort study of patients with nmCRPC treated with novel ARIs, results suggest better tolerability for darolutamide compared with enzalutamide and apalutamide, which may be associated with a clinical effectiveness advantage. Comparative clinical studies are needed to guide treatment decisions in the absence of head-to-head clinical trials.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
HJJHJH完成签到,获得积分10
1秒前
Bob发布了新的文献求助10
2秒前
3秒前
4秒前
HJJHJH发布了新的文献求助50
5秒前
JW完成签到,获得积分10
5秒前
wanci应助张参采纳,获得10
6秒前
谦让的西装完成签到 ,获得积分10
7秒前
李演员完成签到,获得积分10
8秒前
fei菲飞完成签到,获得积分10
8秒前
10秒前
Zhaowx完成签到,获得积分10
10秒前
Theprisoners完成签到,获得积分0
10秒前
木子发布了新的文献求助30
10秒前
10秒前
下课了吧完成签到,获得积分10
11秒前
丘比特应助xialuoke采纳,获得10
12秒前
zgt01发布了新的文献求助10
14秒前
linfordlu完成签到,获得积分0
14秒前
清浅发布了新的文献求助10
15秒前
风趣的涵柏完成签到,获得积分10
16秒前
18秒前
Chen完成签到 ,获得积分10
19秒前
20秒前
木樨完成签到,获得积分10
21秒前
科研顺利完成签到,获得积分10
22秒前
Bin完成签到,获得积分10
23秒前
gszy1975发布了新的文献求助10
23秒前
十曰发布了新的文献求助10
24秒前
25秒前
25秒前
jiaolulu发布了新的文献求助10
30秒前
畅快的念烟完成签到,获得积分10
32秒前
丽莫莫完成签到,获得积分10
32秒前
钙离子完成签到,获得积分10
33秒前
情怀应助OLDBLOW采纳,获得10
34秒前
潇洒日记本完成签到,获得积分10
35秒前
vsvsgo发布了新的文献求助30
36秒前
量子星尘发布了新的文献求助10
36秒前
xiaodong完成签到,获得积分10
36秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038235
求助须知:如何正确求助?哪些是违规求助? 3575992
关于积分的说明 11374009
捐赠科研通 3305760
什么是DOI,文献DOI怎么找? 1819276
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022